183 related articles for article (PubMed ID: 19081868)
1. Bone metastases and lung cancer recurrence on (99m)Tc-depreotide imaging.
Meristoudis G; Ilias I; Batsakis C; Christakopoulou J
Hell J Nucl Med; 2008; 11(3):185-6, author reply 186. PubMed ID: 19081868
[No Abstract] [Full Text] [Related]
2. Soft tissue metastases and lung cancer recurrence detected by Tc-99m depreotide scintigraphy.
Miliziano JS; Bradley YC
Clin Nucl Med; 2002 Jun; 27(6):410-2. PubMed ID: 12045431
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide.
Menda Y; Kahn D
Semin Nucl Med; 2002 Apr; 32(2):92-6. PubMed ID: 11965604
[TBL] [Abstract][Full Text] [Related]
4. Uptake of depreotide in a patient with lung cancer and bone metastases.
Gao Z; Biersack HJ; Bucerius J
Clin Nucl Med; 2005 Jan; 30(1):60-1. PubMed ID: 15604979
[No Abstract] [Full Text] [Related]
5. Contribution of (99m)Tc-depreotide (Neospect) scintigraphy in lung cancer staging.
Karathanos E; Datseris I; Vlontzou E; Zisimopoulos A; Georgiou E
J BUON; 2010; 15(1):147-52. PubMed ID: 20414943
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations.
Herlin G; Kölbeck KG; Menzel PL; Svensson L; Aspelin P; Capitanio A; Axelsson R
Acta Radiol; 2009 Oct; 50(8):902-8. PubMed ID: 19707908
[TBL] [Abstract][Full Text] [Related]
7. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer.
Mena E; Camacho V; Estorch M; Fuertes J; Flotats A; Carrió I
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1399-404. PubMed ID: 15221296
[TBL] [Abstract][Full Text] [Related]
8. Assessment of non-small cell lung cancer viability and necrosis with three radiopharmaceuticals.
Sobic-Saranovic D; Pavlovic S; Jovanovic D; Nebojsa K; Todorovic-Tirnanic M; Subotic D; Artiko V; Obradovic V
Hell J Nucl Med; 2008; 11(1):16-20. PubMed ID: 18392221
[TBL] [Abstract][Full Text] [Related]
9. Tc-99m MDP uptake by adrenal metastases from nonsmall cell carcinoma of the lung.
Ozülker T; Ozülker F; Ozpaçaci T; Ergür S; Mülazimoğlu M
Clin Nucl Med; 2005 Jul; 30(7):514-6. PubMed ID: 15965335
[No Abstract] [Full Text] [Related]
10. Evaluation of pentavalent Tc-99m DMSA scintigraphy in small cell and nonsmall cell lung cancers.
Atasever T; Gündoğdu C; Vural G; Kapucu LO; Karalezli A; Unlü M
Nuklearmedizin; 1997 Oct; 36(7):223-7. PubMed ID: 9394361
[TBL] [Abstract][Full Text] [Related]
11. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
12. Discrepant uptake between 111In-pentetreotide and 99mTc-MDP in bone metastases of small-cell lung cancer.
Meristoudis G; Ilias I; Giannakopoulos V; Batsakis C; Christakopoulou J
Hell J Nucl Med; 2009; 12(3):283-4. PubMed ID: 19936347
[No Abstract] [Full Text] [Related]
13. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules.
Grewal RK; Dadparvar S; Yu JQ; Babaria CJ; Cavanaugh T; Sherman M; Jacobstein J
Cancer J; 2002; 8(5):400-4. PubMed ID: 12416898
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-Depreotide chest SPECT demonstrates pulmonary metastases from renal cell carcinoma.
Shih WJ; Romero RA; Timothy M; Milan PP
J Nucl Med Technol; 2004 Mar; 32(1):19-21. PubMed ID: 14990670
[TBL] [Abstract][Full Text] [Related]
15. False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases.
An YS; Yoon JK; Lee MH; Joh CW; Yoon SN
Clin Nucl Med; 2005 Mar; 30(3):203-4. PubMed ID: 15722832
[No Abstract] [Full Text] [Related]
16. Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma.
Kosuda S; Yokoyama H; Katayama M; Yokokawa T; Kusano S; Yamamoto O
Eur J Nucl Med; 1995 Oct; 22(10):1218-20. PubMed ID: 8542909
[TBL] [Abstract][Full Text] [Related]
17. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
[TBL] [Abstract][Full Text] [Related]
18. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
19. Comparative SPECT findings of Tc-99m depreotide, Tc-99m tetrofosmin, and Tl-201 chloride for bronchogenic carcinoma.
Shih WJ; Bensadoun ES; Hirschowitz E; Kieffer V; Gross K
Clin Nucl Med; 2002 Sep; 27(9):676-9. PubMed ID: 12192295
[No Abstract] [Full Text] [Related]
20. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules.
Blum J; Handmaker H; Lister-James J; Rinne N
Chest; 2000 May; 117(5):1232-8. PubMed ID: 10807805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
